Inhibitor Therapeutics, Inc. (INTI)

Inhibitor Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	13	8	10	16	37	56
Market Cap Growth	-12.81%	-25.02%	-34.56%	-57.47%	-34.06%	332.17%
Enterprise Value	10	5	4	6	42	61
Last Close Price	0.07	0.04	0.06	0.09	0.10	0.15
PE Ratio	-	-	-	-	3.12	-
PB Ratio	-9.88	-6.01	5.22	3.00	4.49	-15.59
P/TBV Ratio	-	-	5.22	3.00	4.49	-
P/OCF Ratio	-	-	-	-	3.17	-
Debt / Equity Ratio	-0.05	-0.05	-	-	0.05	-0.06
Net Debt / Equity Ratio	1.79	1.79	-2.82	-1.67	-1.39	-0.05
Quick Ratio	3.10	3.10	7.90	13.29	17.61	0.05
Current Ratio	3.19	3.19	8.03	13.45	17.64	0.09
Return on Equity (ROE)	-952.30%	-952.30%	-91.88%	-44.57%	517.86%	-
Return on Assets (ROA)	-52.20%	-52.20%	-31.22%	-20.34%	-6.83%	-213.47%
Return on Capital Employed (ROCE)	-196.40%	-196.40%	-73.40%	-41.10%	-5.80%	52.40%
Earnings Yield	-25.84%	-42.50%	-32.24%	-19.12%	32.53%	-0.53%
Buyback Yield / Dilution	-0.14%	-0.14%	-0.18%	53.04%	2.67%	-1.16%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.